Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression

Authors

Ella Daly

Published

December 27, 2017

Abstract

Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants.

Supporters

Support the authors with ResearchCoin

Journal

JAMA Psychiatry

Topics

DOI

10.1001/jamapsychiatry.2017.3739

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression

Authors

Ella Daly

Published

December 27, 2017

Abstract

Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants.

Supporters

Support the authors with ResearchCoin

Journal

JAMA Psychiatry

Topics

DOI

10.1001/jamapsychiatry.2017.3739

Paper

Paper

Paper

Paper

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression

Abstract

Supporters

Journal

Topics

DOI

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression

Abstract

Supporters

Journal

Topics

DOI